Hazel Szeto, SS-31 Peptide, the World's First FDA-Approved Mitochondria-Targeted Drug (Longevity Summit, 2025)

Key Takeaways

• SS‑31 is FDA‑approved for a rare mitochondrial disorder, not eye health
• TikTok users inject SS‑31 off‑label, seeking vision improvement
• Phase‑2 AMD trial showed no efficacy; 86% reported side effects
• Experts say SS‑31 cannot treat myopia, astigmatism, or presbyopia
• Research continues on retinal protection, but results remain unavailable

Pulse Analysis

The surge of interest in SS‑31, also known as elamipretide, stems from its status as the world’s first FDA‑approved mitochondria‑targeted therapy. While the drug received clearance for a rare genetic mitochondrial disorder, social‑media platforms have repurposed it as a quick fix for eye strain and vision clarity. This off‑label enthusiasm bypasses traditional clinical pathways, prompting users to self‑administer injections without medical supervision—a trend that underscores the power of viral content in shaping health‑care consumer behavior.

Clinical evidence, however, paints a starkly different picture. A phase‑2 trial investigating SS‑31 for age‑related macular degeneration failed to achieve any primary endpoints, and a striking 86% of participants reported adverse events ranging from mild injection site reactions to systemic symptoms. Leading ophthalmologists emphasize that the peptide’s mechanism—mitochondrial protection—does not translate to correcting refractive errors such as myopia, astigmatism, or presbyopia, which are fundamentally optical issues. Consequently, the drug offers no proven benefit for the majority of vision problems driving the TikTok narrative.

The broader implications for the biotech market are twofold. First, the episode highlights the regulatory challenge of managing off‑label hype that can inflate perceived demand and distort investment signals. Second, while SS‑31’s retinal‑protective potential remains under investigation, investors and clinicians should await robust data before considering commercial rollout. For consumers, the key takeaway is to rely on evidence‑based treatments and consult qualified eye‑care professionals rather than unverified social‑media claims.